Delving into the Latest Updates on Nanjing KAEDI Biotech, Inc. with Synapse

Overview

Tags

Neoplasms

Gene therapy

Universal CAR-T

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	18

Top 5 Drug Type	Count

Gene therapy	7
Universal CAR-T	5
Monoclonal antibody	3
TCR therapy	2
CAR-T	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	2
MSLN(Mesothelin)	1
NKG2D(NKG2-D type II integral membrane protein)	1
PTP1B(Protein-tyrosine phosphatase 1B)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

17

1

Phase 1 Clinical

Other

7

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KD-021(Nanjing Kaedi Biotechnology Co Ltd) ( MSLN )	Neoplasms More	Phase 1
KD-U496	Neoplasms More	Preclinical
KD-TCR101	Neoplasms More	Preclinical
KD-275 ( CLDN18.2 )	Neoplasms More	Preclinical
KD-010 ( PTP1B )	Neoplasms More	Preclinical